Navigation Links
Par Pharmaceutical Reports Second Quarter 2008 Results
Date:8/7/2008

27,850 32,200

Payables due to distribution agreement

partners 44,885 36,479

Accrued salaries and employee benefits 8,807 16,596

Accrued expenses and other current liabilities 31,196 27,518

Total current liabilities 312,738 312,793

Long-term debt, less current portion - -

Other long-term liabilities 32,108 30,975

Commitments and contingencies - -

Stockholders' equity

Preferred Stock, par value $0.0001 per share,

authorized 6,000,000 shares; none issued and

outstanding - -

Common Stock, par value $0.01 per share,

authorized 90,000,000 shares; issued

37,187,155 and 36,460,461 shares 372 364

Additional paid-in capital 282,033 274,963

Retained earnings 212,718 230,195

Accumulated other comprehensive loss (1,235) (1,362)

Treasury stock, at cost 2,666,226 and

2,604,977 shares (67,604) (66,405)

Total stockholders' equity 426,284 437,755

Total liabilities and stockholders' equity $771,130 $781,523

PAR PHARMACEUTICAL COMPANIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In Thousands, Except Per Share Data)

(Unaudited)

Three Months Ended Six Months Ended

June 28, June 30, June 28, June 30,

2008 2007 2008 2007 <
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. XTELL Launches its Commercial Biorepository Services for Research and Pharmaceutical Companies
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
10. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
11. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)...  OncoSec Medical Inc. ("OncoSec") (NASDAQ: ONCS ... today announced a collaboration with University of California, ... test ImmunoPulse™ IL-12 as an immunotherapy in dogs ... the canine study are to advance the understanding ... and validate key clinical biomarkers. ...
(Date:6/1/2015)... Calif. , June 1, 2015  Asterias ... focused on the emerging field of regenerative medicine, ... a Phase 2 clinical trial of AST-VAC1 in ... leukemia (AML). AST-VAC1 is the Company,s autologous (using ... cancer vaccine. AML is the most common form ...
(Date:5/31/2015)... BARCELONA, Spain , June 1, 2015 /PRNewswire/ ... company dedicated to rare diseases, has selected Veeva ... across sales, marketing, and medical. A complete solution, ... data, multichannel interactions, and compliant content to provide ... and effective commercial execution.      (Logo: ...
(Date:5/31/2015)... Grow Med University (GMU) is a free, ... at their own pace and dip into the rich ... both scientific and other informative articles, to hone their ... harvest yet! , The medical marijuana industry is ... in the U.S. and a slew of other businesses ...
Breaking Biology Technology:OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 2OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 3OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 4Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 2Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 3Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 4Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 5Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 6Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 7Sobi Establishes Global Commercial Operations in the Cloud with Best-in-Class Veeva Commercial Cloud 2Sobi Establishes Global Commercial Operations in the Cloud with Best-in-Class Veeva Commercial Cloud 3Grow Med University: a Brand New Online Hydroponics Course 2
... ATLANTA, Sept. 24 GeoVax Labs, Inc. ... company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), ... in the recently completed Phase 3 trial in Thailand of ... for Infectious Diseases. The completed study represents the first HIV/AIDS ...
... NEW YORK, Sept. 24 Reportlinker.com announces that a ... , Stem Cell Therapeutics Markets ... Political and business events presage change for stem cell ... lift federal funding restrictions on stem-cell research. The U.S. Congress has ...
... , , , ... CALP ), a leading provider of tools and services ... of XenoLight Rediject reagents at the World Molecular Imaging ... in an expanding range of XenoLight reagents for Caliper,s IVIS optical ...
Cached Biology Technology:Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy 2Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy 3Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy 4Reportlinker Adds Stem Cell Therapeutics Markets Report 2Reportlinker Adds Stem Cell Therapeutics Markets Report 3Reportlinker Adds Stem Cell Therapeutics Markets Report 4Reportlinker Adds Stem Cell Therapeutics Markets Report 5Reportlinker Adds Stem Cell Therapeutics Markets Report 6Reportlinker Adds Stem Cell Therapeutics Markets Report 7Caliper Life Sciences Expands Suite of Reagents Supporting the IVIS Family of In Vivo Imaging Systems 2Caliper Life Sciences Expands Suite of Reagents Supporting the IVIS Family of In Vivo Imaging Systems 3
(Date:5/22/2015)... -- According to a new market research ... Emotion, Forensic), by Software (Middleware, Databases), by Hardware (Cameras, Integrated ... Home) - Global Forecast to 2020", published by MarketsandMarkets, ... 2015 to $6.19 Billion by 2020, at a CAGR ... Tables and   43 Figures spread through 140 Pages ...
(Date:5/21/2015)... The Sync Project™ , a global collaboration harnessing ... a collaborative partnership with Berklee,s Institute for Creative ... on original research, joint course development and an internship ... Sync Project and BerkleeICE are exploring the launch of ... academic year.  The course will focus ...
(Date:5/20/2015)... Conn. , May 20, 2015 NXT-ID, ... announces that its wholly owned subsidiary, 3D-ID LLC, a ... under Team Battelle for the biometrics technology portion of ... Suite Contract from the Department of the Army. ... recognition products developed for government, law enforcement and security ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... Louisiana, US - Alligators display the same loyalty to ... in Molecular Ecology . The ten-year-study by scientists from ... of females chose to remain with their partner, often for ... Ruth Elsey, Tracey Tuberville and Stacey Lance, spent a decade ...
... in Spanish . , Individuals who follow ... grains and fish- appear less likely to develop depression, according ... the October issue of Archives of General Psychiatry . ... to be lower in Mediterranean than Northern European countries, according ...
... , This release is available in German . ... selectively transcribe parts of the DNA that makes up its genome ... proteins synthesized by a cell in turn determines its structure and ... crucial that the appropriate stretches of DNA are transcribed in each ...
Cached Biology News:Loyal alligators display the mating habits of birds 2Mediterranean diet associated with reduced risk of depression 2How RNA polymerase II gets the go-ahead for gene transcription 2How RNA polymerase II gets the go-ahead for gene transcription 3
WTAP Antibody...
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
...
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Biology Products: